Committees

Published: 15 May 2018

Summary of Recommendations from the 106th meeting of the Medicines Assessment Advisory Committee held in Wellington on Tuesday 27 MARCH 2018 at 9:30 am

5.

Applications for consent to distribute a new medicine under section 20 of the Medicines Act 1981 (referred by the Minister of Health under section 22(2))

5.1

Liposomal Doxorubicin SUN, 2 mg/mL concentrate for infusion (TT50-9159) Pharmacy Retailing (NZ) Ltd

The Committee recommended that the Minister of Health should defer making a decision to grant consent to distribute this medicine under Section 20 of the Medicines Act 1981 until further information has been provided.

5.2

Nasovac-S Influenza Vaccine (TT50-9244) Te Arai Bioframa Limited


The application was withdrawn by Te Arai Biofarma Limited prior to the meeting on 22 February 2018.

7

General business

7.1

Observers


Comments for consultation on observers at Ministerial Advisory Committee meetings have closed.  The Secretary will analyse these comments and report back at the next meeting.

7.2

Publication of MAAC Outcomes


The Committee agreed that the current process for publishing meeting dates, agendas and a summary of recommendations for the MAAC is fit for purpose and no changes are currently required.